Bedrijfsoverzicht
enVVeno Medical Corporation is a clinical-stage medical device company dedicated to developing bioprosthetic tissue-based solutions aimed at enhancing the standard of care for venous disease treatment. The enterprise operates within the Healthcare sector, specifically focusing on the Medical Devices industry, where innovation in surgical implants and therapeutic technologies is critical for patient outcomes. The company's current scale is defined by a market capitalization of $7.24M and an employee base of 33 individuals, while reported annual revenue and specific growth rates are not available in the provided financial data. These valuation and operational metrics indicate that enVVeno Medical Corporation functions as a small-cap entity in a high-growth potential niche, characterized by significant early-stage development costs that have not yet been offset by substantial revenue generation.
Financiële gezondheid
The company reports a net income of $-19,472,000 and an EBITDA of $-20,763,000, while specific revenue figures for the trailing twelve months are not disclosed in the available data. The substantial gap between the reported net income loss and the EBITDA loss suggests that the company incurs significant non-operating expenses, such as interest payments or other financing costs, which widen the disparity between operating profitability and bottom-line earnings. Free cash flow stands at $-9,209,875, indicating a heavy burn rate that currently limits the company's financial flexibility and its ability to fund operations without external capital injections. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the typical financial profile of a pre-revenue or early-stage clinical company that has not yet achieved commercial sales. The company holds $28.21M in cash assets against $700,000 in debt, resulting in a debt-to-equity ratio of 2.58, which presents a unique balance sheet dynamic where high leverage exists due to minimal equity rather than excessive debt burden. This cash position provides a substantial buffer against operational expenditures, though the high debt-to-equity ratio technically classifies the balance sheet as leveraged in traditional accounting terms. The current ratio is reported at 13.58, signifying an extremely strong short-term liquidity position with current assets vastly exceeding current liabilities. Furthermore, the return on equity is -56.2% and the return on assets is -35.1%, revealing that management effectiveness is currently measured by the rate at which the company consumes shareholder and asset value to fund its clinical development pipeline.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not available due to losses, while the forward P/E is listed as -9.29, implying that the market prices in anticipated future earnings growth or that negative earnings persist in analyst models. The price-to-book ratio stands at 0.27, indicating that the market values the company's equity at a significant discount to its book value, which often occurs in capital-intensive biotech firms with intangible assets not fully captured on the balance sheet. The price-to-sales ratio is not available in the current dataset, and the EV/EBITDA multiple is 0.98, suggesting that the enterprise value is priced at less than one times its adjusted earnings before interest, taxes, depreciation, and amortization. The stock's 52-week trading range spans from a low of $8.67 to a high of $196.70, meaning the current share price sits at the lower end of this historical volatility spectrum relative to the 52-week high. The beta value of 1.09 indicates that the stock's price volatility is slightly higher than the broader market, reflecting the inherent risks associated with clinical-stage development and regulatory uncertainty in the medical device sector.
Growth & Income
Specific revenue growth and earnings growth rates for the year-over-year period are not available in the provided facts, preventing a direct comparison of the pace at which earnings or sales are expanding. As the company does not pay a dividend, the dividend yield is not available and the payout ratio is 0.0%, meaning the firm does not distribute cash to shareholders but instead retains all earnings to fund research and development. Consequently, the company reinvests its limited earnings and substantial cash reserves directly into the advancement of its lead product, the VenoValve, rather than providing income distributions. This growth and income profile characterizes enVVeno Medical Corporation as a pure-play speculative asset where returns are derived entirely from potential future commercialization of its bioprosthetic tissue-based solutions rather than current profitability or dividend yields.